PMID- 27048254
OWN - NLM
STAT- MEDLINE
DCOM- 20190301
LR  - 20190301
IS  - 2005-6648 (Electronic)
IS  - 1226-3303 (Print)
IS  - 1226-3303 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Jan
TI  - Drug survival and the associated predictors in South Korean patients with 
      rheumatoid arthritis receiving tacrolimus.
PG  - 193-202
LID - 10.3904/kjim.2015.385 [doi]
AB  - BACKGROUND/AIMS: To investigate the drug survival rate of tacrolimus (TAC) and 
      analyze the potential predictors of this rate in patients with rheumatoid 
      arthritis (RA) in routine care. METHODS2018-01-16: In this retrospective 
      longitudinal study, we enrolled 102 RA patients treated with TAC from April 2009 
      to January 2014 at a tertiary center in South Korea. The causes of TAC 
      discontinuation were classified as lack of efficacy (LOE), adverse events (AEs), 
      and others. The drug survival rate was estimated using the Kaplan-Meier method 
      and the predictors of this rate were identified by Cox-regression analyses. 
      RESULTS: TAC was discontinued in 27 of 102 RA patients (26.5%). The overall 1-, 
      2-, 3-, and 4-year TAC continuation rates were 81.8%, 78.4%, 74.2%, and 69.1%, 
      respectively and the median follow-up period from the start of TAC was 32.5 
      months. The number of TAC discontinuations due to LOE, AEs, and others were 15 
      (55.6%), 11 (40.7 %), and 1 (3.7%), respectively. The baseline high disease 
      activity was a significant risk factor for TAC discontinuation after adjusting 
      for confounding factors (hazard ratio [HR], 2.49; 95% confidence interval [CI], 
      1.16 to 5.35; p = 0.019). In addition, underlying interstitial lung disease was 
      significantly associated with TAC withdrawal due to AEs (HR, 3.49; 95% CI, 1.06 
      to 11.46; p = 0.039). CONCLUSIONS: In our study, TAC showed a good overall 
      survival rate in patients with RA in real clinical practice. This suggests that 
      the long-term TAC therapy has a favorable efficacy and safety profile for 
      treating RA.
FAU - Park, Eun-Young
AU  - Park EY
AD  - Division of Rheumatology, Department of Internal Medicine, Pusan National 
      University Hospital, Busan, Korea.
FAU - Lee, Seung-Geun
AU  - Lee SG
AD  - Division of Rheumatology, Department of Internal Medicine, Pusan National 
      University Hospital, Busan, Korea.
FAU - Park, Eun-Kyoung
AU  - Park EK
AD  - Division of Rheumatology, Department of Internal Medicine, Pusan National 
      University Hospital, Busan, Korea.
FAU - Koo, Dong-Wan
AU  - Koo DW
AD  - Division of Rheumatology, Department of Internal Medicine, Pusan National 
      University Hospital, Busan, Korea.
FAU - Park, Ji-Heh
AU  - Park JH
AD  - Division of Rheumatology, Department of Internal Medicine, Pusan National 
      University Hospital, Busan, Korea.
FAU - Kim, Geun-Tae
AU  - Kim GT
AD  - Division of Rheumatology, Department of Internal Medicine, Kosin University 
      College of Medicine, Busan, Korea.
FAU - Tag, Hee-Sang
AU  - Tag HS
AD  - Division of Rheumatology, Department of Internal Medicine, Kosin University 
      College of Medicine, Busan, Korea.
FAU - Kim, Hyun-Ok
AU  - Kim HO
AD  - Division of Rheumatology, Department of Internal Medicine, Gyeongsang National 
      University School of Medicine, Jinju, Korea.
FAU - Suh, Young-Sun
AU  - Suh YS
AD  - Division of Rheumatology, Department of Internal Medicine, Gyeongsang National 
      University School of Medicine, Jinju, Korea.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160406
PL  - Korea (South)
TA  - Korean J Intern Med
JT  - The Korean journal of internal medicine
JID - 8712418
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Kaplan-Meier Estimate
MH  - Republic of Korea
MH  - Retrospective Studies
MH  - Tacrolimus/*therapeutic use
MH  - Treatment Outcome
MH  - Withholding Treatment
PMC - PMC5768536
OTO - NOTNLM
OT  - Arthritis, rheumatoid
OT  - Drug survival
OT  - Safety
OT  - Tacrolimus
OT  - Treatment outcome
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2016/04/07 06:00
MHDA- 2019/03/02 06:00
PMCR- 2018/01/01
CRDT- 2016/04/07 06:00
PHST- 2015/11/29 00:00 [received]
PHST- 2015/12/21 00:00 [revised]
PHST- 2015/12/28 00:00 [accepted]
PHST- 2016/04/07 06:00 [pubmed]
PHST- 2019/03/02 06:00 [medline]
PHST- 2016/04/07 06:00 [entrez]
PHST- 2018/01/01 00:00 [pmc-release]
AID - kjim.2015.385 [pii]
AID - kjim-2015-385 [pii]
AID - 10.3904/kjim.2015.385 [doi]
PST - ppublish
SO  - Korean J Intern Med. 2018 Jan;33(1):193-202. doi: 10.3904/kjim.2015.385. Epub 
      2016 Apr 6.